<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04929366</url>
  </required_header>
  <id_info>
    <org_study_id>0101-17-ZIV</org_study_id>
    <nct_id>NCT04929366</nct_id>
  </id_info>
  <brief_title>Is Hemodialysis Associated With Cardiac Markers Change?</brief_title>
  <official_title>Effects of Hemodialysis With Cooled Dialysate on High Sensitive Cardiac Troponin I (TnI) and Brain Natriuretic Peptide (NT proBNP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ziv Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ziv Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hemodialysis (HD) triggers recurrent and cumulative ischemic insults to the brain and the&#xD;
      heart. Cooled dialysate may have a protective effect on major organs and improve hemodynamic&#xD;
      tolerability of dialysis. The aim of the study was to compare HD with cooled dialysate with&#xD;
      routine dialysis in terms of hemodynamic stability and levels of high sensitivity Troponin I&#xD;
      (hs-TnI) and N-terminal pro b-type natriuretic peptide (NTproBNP) post dialysis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 18, 2017</start_date>
  <completion_date type="Actual">November 16, 2020</completion_date>
  <primary_completion_date type="Actual">November 16, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of hypothermic dialysis with routine dialysis in terms of hemodynamic stability</measure>
    <time_frame>one year</time_frame>
    <description>For each patient, four blood pressure measurements including systolic blood pressure, diastolic blood pressure and mean arterial pressure were performed at the beginning, after 2 hours, after 3 hours after 4 hours (end of hemodialysis).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessments of the levels of high sensitivite Troponin I (hs-TnI) and N-terminal pro b-type natriuretic peptide (NTproBNP) post dialysis</measure>
    <time_frame>6 months</time_frame>
    <description>Blood samples were collected at the beginning of the dialysis session, and a second sample was taken in the last 5 minutes of hemodialysis in order to evaluate the relationship between hemodialysis with cooled dialysate (hypothermic dialysis) and the myocardial markers hs-TnI and NTproBNP and to monitor hypothermic hemodiaysis treatment response.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <arm_group>
    <arm_group_label>End-stage kidney patients treated in the dialysis unit group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>End-stage kidney patients treated in the dialysis unit group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hypothermic dialysis followed with routine dialysis</intervention_name>
    <description>Hypothermic dialysis (35.5 degrees Celsius dialysate) followed with routine dialysis (36.5 degrees Celsius dialysate)</description>
    <arm_group_label>End-stage kidney patients treated in the dialysis unit group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Routine dialysis followed with hypothermic dialysis</intervention_name>
    <description>Routine dialysis (36.5 degrees Celsius dialysate) followed with hypothermic dialysis (35.5 degrees Celsius dialysate)</description>
    <arm_group_label>End-stage kidney patients treated in the dialysis unit group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with renal insufficiency treated with dialysis for a period of at least three&#xD;
             months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who experienced myocardial infarction during the three months prior to the&#xD;
             start of the study&#xD;
&#xD;
          -  Patients who underwent vascular surgery during the last month&#xD;
&#xD;
          -  Patients who experienced chest pain at rest during the last week before the start of&#xD;
             the trial - Patients who had to discontinue dialysis prematurely due to hemodynamic&#xD;
             instability.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Younes Bathish, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ziv Medical Centre, Safed, Israel / Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nephrology Department, Ziv Medical Center</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ziv Hospital</investigator_affiliation>
    <investigator_full_name>Osamah Hussein</investigator_full_name>
    <investigator_title>Head of Internal Medicine A</investigator_title>
  </responsible_party>
  <keyword>End-Stage Kidney Disease</keyword>
  <keyword>Hypothermic hemodialysis</keyword>
  <keyword>Cardiovascular events</keyword>
  <keyword>Troponin T</keyword>
  <keyword>Brain natriuretic peptide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

